Journal of Vascular Medicine & Surgery

Department of Nephrology, The First Affiliated Hospital of Xi’an Jiao Tong University, Shaanxi Xi’an, China

Publications

• Research Article   
  Long-Term Prognosis of AL Amyloidosis in Patients Treated with Bortezomib or Thalidomide
  Author(s): Yuemeng Sun, Xiaoyang Yu, Ping Lan, Wanhong Lu, Jiping Sun, Dan Niu, Yaning Hao, Dapeng Hao, Jing Lv, Liyi Xie* and Jie Feng*
  
  Introduction: AL amyloidosis has become a common secondary cause in elderly male patients presenting with nephrotic syndrome. Daratumumab-CyBorD regimen is approved as the standard first-line regimen for AL-amyloidosis. We aim to analyze the prognosis of patients treated with bortezomib-based regimen and other alternative regimens. Method: We retrospectively collected the baseline and follow up data of newly diagnosed AL amyloidosis patients. Hematological and renal response rate were compared among different regimens and overall survival and renal survival were analyzed. Subgroup analysis of Mayo stage III patients was also performed. Results: 72 cases were included, 48.6% of whom had cardiac involvement. Overall response rate in patients treated with bortezomib-based regimen was 67.4%, including 27.9% Complete Re.. View more»
  

  Abstract HTML PDF